Janus kinase family (JAK family) (JAK)

The Janus kinase (JAK) family consists of four intracellular non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and TYK2 (UniProt: P23458, O60674, P52333, P29597). These enzymes are essential components of the JAK-STAT signaling pathway, which transmits signals from extracellular cytokines and growth factors to the nucleus to regulate gene expression (PMID: 28753374). In peripheral blood mononuclear cells (PBMCs), JAK signaling is critical for the activation and differentiation of T cells, B cells, and monocytes, making it a central regulator of the immune response. Dysregulation of this pathway is a hallmark of numerous autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as hematologic malignancies like myelofibrosis (StatPearls: Janus Kinase Inhibitors). Therapeutic strategies involve small-molecule JAK inhibitors that compete with ATP for the kinase domain, effectively blocking downstream signaling and reducing systemic inflammation. Monitoring JAK signaling in patient PBMCs, often through phosphorylated STAT (pSTAT) assays, provides a direct measure of target engagement and drug efficacy in clinical settings.

Other names

Janus kinasesJAK-STAT signaling pathwayJAK familyJAKs

JAK inhibitors competitively bind to the ATP-binding pocket within the catalytic JH1 domain of Janus kinases, preventing the phosphorylation of STAT proteins and subsequent gene transcription (PMID: 28753374).